DRW Securities’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

DRW Securities’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,000	Closed	-$166K	–	180
2018 Q1	$166K	Buy	2,000 +1,000	+100%	+$113K	0.01%	129
2017 Q4	$149K	Buy	1,000 +375	+60%	+$36K	0.02%	427
2017 Q3	$39K	Hold	625	–	–	0.01%	60
2017 Q2	$29K	Buy	+625	New	+$31.9K	0.01%	68

Other funds holding SRRA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DRW Securities's SRRA Position: Q2 2018 in Review

DRW Securities sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2018, closing a stake of 2,000 shares — an estimated $166K sold.

DRW Securities first reported a position in SRRA in Q2 2017 and held it in 4 quarters. The position peaked at $166K in Q1 2018. 70 funds tracked by Wall St. Rank hold SRRA as of Q2 2018.

DRW Securities reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
DRW Securities sold 2,000 Sierra Oncology, Inc. Common Stock shares in Q2 2018, an estimated $166K.
DRW Securities first reported a position in Sierra Oncology, Inc. Common Stock in Q2 2017 and held it in 4 quarters.
DRW Securities's Sierra Oncology, Inc. Common Stock position peaked at $166K in Q1 2018.
70 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2018.

Based on DRW Securities's 13F filing for Q2 2018, filed 14 Aug 2018.